Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N2'-Deacetyl-N2'-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-chimerised anti-CD138 IgG4 Monoclonal Antibody

EU orphan designation number: EU/3/08/593   
Active ingredient: N2'-Deacetyl-N2'-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-chimerised anti-CD138 IgG4 Monoclonal Antibody
Indication: Treatment of multiple myeloma
Sponsor: Biotest AG
Landsteinerstraße 5, 63303 Dreieich, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/12/2008 Orphan designation EMEA/OD/068/08 (2008)8096 of 03/12/2008